{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T08:10:02Z","timestamp":1747037402592,"version":"3.40.5"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZC20230301"],"award-info":[{"award-number":["GZC20230301"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-010"],"award-info":[{"award-number":["2022-PUMCH-B-010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04174-2","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:04:21Z","timestamp":1738944261000},"page":"431-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temozolomide as neoadjuvant therapy for bladder paraganglioma"],"prefix":"10.1007","volume":"88","author":[{"given":"Yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"10","key":"4174_CR1","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1210\/clinem\/dgac427","volume":"107","author":"K Yu","year":"2022","unstructured":"K. Yu, A.L. Ebbehoj, H. Obeid, et al., Presentation, management, and outcomes of urinary bladder paraganglioma: results from a Multicenter Study. J. Clin. Endocrinol. Metab. 107(10), 2811\u20132821 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac427.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4174_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"M.S. Tomar, A. Kumar, C. Srivastava, A. Shrivastava, Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim. Biophys. Acta Rev. Cancer 1876(2), 188616 (2021). https:\/\/doi.org\/10.1016\/j.bbcan.2021.188616.","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"4174_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","volume":"77","author":"A Thomas","year":"2017","unstructured":"A. Thomas, M. Tanaka, J. Trepel, W.C. Reinhold, V.N. Rajapakse, Y. Pommier, Temozolomide in the era of precision medicine. Cancer Res. 77(4), 823\u2013826 (2017). https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2983.","journal-title":"Cancer Res."},{"issue":"5","key":"4174_CR4","doi-asserted-by":"publisher","first-page":"e1937","DOI":"10.1210\/clinem\/dgaa982","volume":"106","author":"D Granberg","year":"2021","unstructured":"D. Granberg, C.C. Juhlin, H. Falhammar, Metastatic pheochromocytomas and abdominal paragangliomas. J. Clin. Endocrinol. Metab. 106(5), e1937\u2013e1952 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa982.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"4174_CR5","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","volume":"47","author":"PM Patel","year":"2011","unstructured":"P.M. Patel, S. Suciu, L. Mortier, et al., Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur. J. Cancer 47(10), 1476\u20131483 (2011). https:\/\/doi.org\/10.1016\/j.ejca.2011.04.030.","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"4174_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s00381-006-0081-z","volume":"22","author":"G Barone","year":"2006","unstructured":"G. Barone, P. Maurizi, G. Tamburrini, R. Riccardi, Role of temozolomide in pediatric brain tumors. Childs Nerv. Syst. 22(7), 652\u2013661 (2006). https:\/\/doi.org\/10.1007\/s00381-006-0081-z.","journal-title":"Childs Nerv. Syst."},{"issue":"11","key":"4174_CR7","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"J. Hadoux, J. Favier, J.Y. Scoazec, et al., SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int. J. Cancer 135(11), 2711\u20132720 (2014). https:\/\/doi.org\/10.1002\/ijc.28913.","journal-title":"Int. J. Cancer"},{"issue":"9","key":"4174_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/ERC-21-0392","volume":"29","author":"K Perez","year":"2022","unstructured":"K. Perez, H. Jacene, J.L. Hornick, et al., SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr. Relat. Cancer 29(9), 533\u2013544 (2022). https:\/\/doi.org\/10.1530\/ERC-21-0392.","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04174-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:47:39Z","timestamp":1747036059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04174-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}